Bristol-Myers Squibb remains a solid, undervalued investment but is no longer a compelling 'Buy' due to muted growth prospects. BMY's growth portfolio now surpasses its legacy portfolio, yet overall ...

Bristol-Myers Squibb stock closed at USD 62.84 on the NYSE on September 17, 2026, about 8.4% below its 52-week high after a ...

Bristol-Myers Squibb Company (NYSE:BMY) said its experimental CAR-T cell therapy, arlocabtagene autoleucel (arlo-cel), met ...

CEO Christopher Boerner opened by highlighting, “2025 was a year of focused execution across the business. We believe our results further demonstrate the ongoing strength in our growth portfolio as we ...

Bristol Myers Squibb has faced patent cliffs in recent years and will face more in the next few years. The company's portfolio of newer drugs, along with its deep pipeline, can help it overcome this ...

Bristol-Myers Squibb stock (ISIN US1078421011) is trading close to USD 63.60 on the New York Stock Exchange as of September ...

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.

Detailed price information for Bristol-Myers Squibb (BMY-N) from The Globe and Mail including charting and trades.

AbbVie's immunology franchise is firing on all cylinders while Bristol Myers Squibb navigates revenue declines and legal ...

Bristol-Myers Squibb (NYSE:BMY) is funding lung cancer screening research in India that targets risks beyond smoking. The ...